In April 2021, the US paused Janssen (J&J) COVID-19 vaccination because of reported blood clots post vaccination. This paper explores how vaccine decision-making--receiving a J&J vaccine right away vs waiting for a Pfizer vaccine--changed during the pause. In an opt-in internet-based survey April 2021 with 915 participants, 37 % were not vaccinated. Of these, 18 % would accept a J&J vaccine, 5 % would wait 1 month for a Pfizer vaccine, 25 % would wait 3 months, and 52 % would not want any vaccine. Among the unvaccinated, 56 % had heard of blood clots; 61 % of these did not want any vaccine, compared to 41 % of those who had not heard of blood clots. Moreover, among those vaccine hesitant in general, 11 % would still obtain a J&J vaccine if offered right away. These findings may suggest spillover of brand-specific adverse event concerns to the vaccine product as a whole.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477674 | PMC |
| http://dx.doi.org/10.1016/j.jvacx.2023.100373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials.
Rev Esp Cardiol (Engl Ed)
January 2025
Department of Cardiology, Internal Medicine II, Medical University of Vienna, Vienna, Austria. Electronic address:
Introduction And Objectives: Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent.
Methods: A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe.
A mouse model of deep vein thrombosis by inferior vena cava hypoperfusion using ameroid constrictors.
Sci Rep
January 2025
Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Kanagawa, Japan.
Traditional mouse models for deep vein thrombosis (DVT), frequently utilized in research focused on cancer-associated thrombosis (CAT), reliably induce thrombus formation by obstructing blood flow (BF) in the inferior vena cava (IVC), which does not occur in humans. Therefore, to develop a new DVT model for CAT studies, we implanted an ameroid constrictor (AC), a hygroscopic casein C-shape device, around the IVC and aorta of immunocompromised mice. We evaluated the thrombus 3 and 8 days post-AC implantation and compared it with the traditional model 2 days post-vena cava ligation.
View Article and Find Full Text PDFCongenital disorders of glycosylation type 1A associated with cerebral hemorrhagic infarction: illustrative case.
J Neurosurg Case Lessons
January 2025
Department of Neurosurgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Background: Cases of congenital disorders of glycosylation (CDGs) are rare, and the occurrence of hemorrhagic infarction is also rare. The etiology is unclear.
Observations: A 3-year-old Asian boy with CDG type 1A was hospitalized with pneumonia.
Clinical Impact of Pancreatic and Peripancreatic Hemorrhage Associated With Acute Pancreatitis.
J Comput Assist Tomogr
November 2024
NYU Department of Radiology, New York, NY.
Purpose: The significance of pancreatitis-associated hemorrhage outside the context of a ruptured pseudoaneurysm remains unclear. This study aims to characterize the clinical significance of pancreatic hemorrhage during acute pancreatitis (AP).
Methods: This retrospective study included adult patients diagnosed with hemorrhagic pancreatitis (HP) from 2010 to 2021.
Determining the perceptions and practices of oncologists regarding venous thromboembolism risk assessment in ambulatory cancer patients: A qualitative study.
PLoS One
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
Cancer-associated thrombosis (CAT) can increase morbidity and mortality for cancer patients. Therefore, guidelines recommend predicting VTE risk and thromboprophylaxis for high-risk patients. Many studies critique oncologists' adherence to thromboprophylaxis guidelines for cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!